InnoCare’s Tafasitamab + Lenalidomide Receives Approval from China Regulatory Authority to Treat r/r Diffuse Large B-Cell Lymphoma
- Minjuvi (tafasitamab) + lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province under the early access program in Boao Lecheng International Medical Tourism Pilot Zonea whereas, the first prescription of tafasitamab + lenalidomide was filled at the Ruijin Hainan Hospital in China for an eligible DLBCL patient
- Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAB and it is not approved by the NMPA for any indication except this early access program
- Earlier, this combination received conditional approval by the US FDA & the EMA for the treatment of r/r DLBCL patients who are not eligible for autologous stem cell transplant
Ref: Bussinesswire | Image: InnoCare
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.